Active acromegaly is associated with significant comorbidity and reduced quality of life.
However, the prevalence of comorbidity after long-term remission is not established …

Context: In clinical practice, patients with acromegaly may be switched from therapy with
long-acting somatostatin analogs to pegvisomant. The effect of changing therapies on …

Context: Persistently elevated GH and IGF-I levels are associated with increased mortality.
Their response to somatostatin analogs (SSA) is variable. Objective: The objective of this …

Summary Background The GH/IGF‐I axis has a relevant role to play in the cardiovascular
system but its implication in the pathogenesis of hypertension in the normal population and …

Acromegaly is an insidious disease that occurs, in the majority of cases, as a result of a
pituitary adenoma that hypersecretes growth hormone (GH). The clinical consequences of …

Objective To describe a case of muscle weakness in a patient with acromegaly and to
review the pathophysiologic features of this disorder. Methods We present the clinical …

Acromegaly is associated with insulin resistance and an increased incidence of
cardiovascular disease. However, it remains unclear to what extent the effects of growth …

Acromegaly is associated with considerable morbidity and excess mortality; however, after
effective treatment, both morbidity and mortality risks improve. Growth hormone excess in …

Background Skin is enlarged and doughy in acromegaly. Alterations have been reported in
the structure of the extracellular matrix (ECM) and in the mechanical properties of the …

This book reviews the pathophysiology and physical manifestations of acromegaly and
discusses the multiple treatment options now available for the management of the patient …